Halozyme Therapeutics, Inc. (0J2O.L)
USD 48.78
(0.12%)
USD 48.78
(0.12%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.49 Billion USD | -0.45% |
| 2022 | 1.5 Billion USD | 71.8% |
| 2021 | 876.67 Million USD | 120.7% |
| 2020 | 397.22 Million USD | -1.33% |
| 2019 | 402.58 Million USD | 218.55% |
| 2018 | 126.38 Million USD | -37.54% |
| 2017 | 202.35 Million USD | -6.59% |
| 2016 | 216.62 Million USD | 334.69% |
| 2015 | 49.83 Million USD | -0.05% |
| 2014 | 49.86 Million USD | 0.18% |
| 2013 | 49.77 Million USD | 59.98% |
| 2012 | 31.11 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 400 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.53 Billion USD | 2.23% |
| 2024 Q2 | 1.53 Billion USD | 0.04% |
| 2024 Q3 | 1.5 Billion USD | -1.89% |
| 2023 Q4 | 1.49 Billion USD | 0.11% |
| 2023 Q2 | 1.49 Billion USD | 0.11% |
| 2023 Q1 | 1.49 Billion USD | -0.78% |
| 2023 Q3 | 1.49 Billion USD | 0.11% |
| 2023 FY | 1.49 Billion USD | -0.45% |
| 2022 FY | 1.5 Billion USD | 71.8% |
| 2022 Q4 | 1.5 Billion USD | 0.11% |
| 2022 Q1 | 877.64 Million USD | 0.11% |
| 2022 Q2 | 1.24 Billion USD | 41.99% |
| 2022 Q3 | 1.5 Billion USD | 20.73% |
| 2021 Q2 | 874.73 Million USD | 0.11% |
| 2021 Q1 | 873.77 Million USD | 119.97% |
| 2021 Q4 | 876.67 Million USD | 0.11% |
| 2021 Q3 | 875.7 Million USD | 0.11% |
| 2021 FY | 876.67 Million USD | 120.7% |
| 2020 Q1 | 389.43 Million USD | -3.27% |
| 2020 Q3 | 393.63 Million USD | 0.91% |
| 2020 Q4 | 397.22 Million USD | 0.91% |
| 2020 FY | 397.22 Million USD | -1.33% |
| 2020 Q2 | 390.07 Million USD | 0.17% |
| 2019 Q4 | 402.58 Million USD | 530.57% |
| 2019 FY | 402.58 Million USD | 218.55% |
| 2019 Q3 | 63.84 Million USD | -24.85% |
| 2019 Q2 | 84.96 Million USD | -19.4% |
| 2019 Q1 | 105.4 Million USD | -16.6% |
| 2018 FY | 126.38 Million USD | -37.54% |
| 2018 Q4 | 126.38 Million USD | -13.71% |
| 2018 Q3 | 146.46 Million USD | -11.79% |
| 2018 Q2 | 166.04 Million USD | -10.32% |
| 2018 Q1 | 185.15 Million USD | -8.5% |
| 2017 Q2 | 211.03 Million USD | -1.4% |
| 2017 FY | 202.35 Million USD | -6.59% |
| 2017 Q1 | 214.03 Million USD | -1.2% |
| 2017 Q4 | 202.35 Million USD | -2.18% |
| 2017 Q3 | 206.85 Million USD | -1.98% |
| 2016 Q4 | 216.62 Million USD | 2.08% |
| 2016 FY | 216.62 Million USD | 334.69% |
| 2016 Q2 | 208.13 Million USD | 6.18% |
| 2016 Q1 | 196.01 Million USD | 293.35% |
| 2016 Q3 | 212.19 Million USD | 1.95% |
| 2015 FY | 49.83 Million USD | -0.05% |
| 2015 Q3 | 49.79 Million USD | 0.08% |
| 2015 Q1 | 49.71 Million USD | -0.29% |
| 2015 Q2 | 49.75 Million USD | 0.08% |
| 2015 Q4 | 49.83 Million USD | 0.08% |
| 2014 FY | 49.86 Million USD | 0.18% |
| 2014 Q2 | 49.81 Million USD | 0.05% |
| 2014 Q3 | 49.83 Million USD | 0.04% |
| 2014 Q1 | 49.79 Million USD | 0.04% |
| 2014 Q4 | 49.86 Million USD | 0.05% |
| 2013 Q4 | 49.77 Million USD | 54.08% |
| 2013 Q2 | 31.81 Million USD | 2.19% |
| 2013 Q1 | 31.13 Million USD | 0.08% |
| 2013 FY | 49.77 Million USD | 59.98% |
| 2013 Q3 | 32.3 Million USD | 1.52% |
| 2012 FY | 31.11 Million USD | 0.0% |
| 2012 Q4 | 31.11 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q2 | - USD | -100.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | 135.93 Million USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | 400 Thousand USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -4003.481% |
| Dynavax Technologies Corporation | 256.91 Million USD | -483.56% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -3510.297% |
| Perrigo Company plc | 4.07 Billion USD | 63.194% |
| Illumina, Inc. | 2.26 Billion USD | 33.72% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 95.706% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -149824.8% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 84.308% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 89.465% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -762.862% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 44.532% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -5454.828% |
| Waters Corporation | 2.35 Billion USD | 36.352% |
| Biogen Inc. | 7.33 Billion USD | 79.569% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -3834.621% |
| Evolus, Inc. | 126.54 Million USD | -1084.745% |
| Adicet Bio, Inc. | 17.7 Million USD | -8368.892% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -3373.135% |
| bluebird bio, Inc. | 330.32 Million USD | -353.869% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -177.152% |
| FibroGen, Inc. | 170.45 Million USD | -779.556% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 45.183% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -7078.851% |
| Homology Medicines, Inc. | 44.05 Million USD | -3303.205% |
| Geron Corporation | 85.89 Million USD | -1645.361% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 37.48% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -236.865% |
| Myriad Genetics, Inc. | 145 Million USD | -933.964% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -118887.937% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -1199.783% |
| Zoetis Inc. | 6.8 Billion USD | 77.962% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -33958.337% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 30.839% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -32.223% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -85.459% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -4027.545% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -3.145% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -2490.628% |
| Verastem, Inc. | 41.55 Million USD | -3507.691% |
| Nektar Therapeutics | 230.4 Million USD | -550.712% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -704.438% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -48671.893% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -7.334% |
| OPKO Health, Inc. | 326.56 Million USD | -359.098% |
| Exelixis, Inc. | 189.94 Million USD | -689.311% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -249.965% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -992779.47% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -983.201% |
| Imunon, Inc. | 1.13 Million USD | -131494.594% |
| Blueprint Medicines Corporation | 774.12 Million USD | -93.671% |
| Insmed Incorporated | 1.2 Billion USD | -24.523% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -2530.814% |
| TG Therapeutics, Inc. | 110.79 Million USD | -1253.173% |
| Incyte Corporation | 38.28 Million USD | -3815.815% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -70.854% |